Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, Brown MJ; BrigHTN Investigators.
Freeman MW, et al.
N Engl J Med. 2023 Feb 2;388(5):395-405. doi: 10.1056/NEJMoa2213169. Epub 2022 Nov 7.
N Engl J Med. 2023.
PMID: 36342143
Clinical Trial.